نتایج جستجو برای: pegylated interferon sa
تعداد نتایج: 99564 فیلتر نتایج به سال:
background the hepatitis c virus (hcv) infection has been identified as a leading cause of progressive liver diseases worldwide. despite new treatment strategies, pegylated interferon alfa-2a (peg-ifnα-2a), in combination with ribavirin (rbv), still represents the gold standard of therapy for hepatitis c in developing countries. results in this study, a significant association was observed betw...
Hepatitis C virus infection is the leading cause of chronic liver disease in the United States of America. Pegylated interferon α and ribavirin combination is the mainstay of treatment. Severe pulmonary toxicities are rarely reported. We report here a case of severe form of organizing pneumonia secondary to pegylated interferon α therapy presenting as acute respiratory failure. Patient has near...
The Philadelphia negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis, are associated with substantial vascular and transformative complications. Standard therapy for high-risk disease, particularly in patients that have failed initial therapy, remains controversial. Non-pegylated interferon has previously been shown to be effective in...
Cardiac arrhythmias and syncope are rare consequence of therapy with pegylated interferon. We report a 55-year-old Egyptian woman who developed palpitation and syncopal attacks twice within 3 months after starting therapy with pegylated interferon alpha2b and ribavirin for the treatment of chronic hepatitis C virus. Hepatitis C virus-RNA was undetectable after 12 week. The electrocardiogram hol...
Autoimmune manifestations are common both in patients chronically infected by hepatitis C virus, and in patients transplanted for non-autoimmune diseases. A correlation between interferon based treatment and autoimmune diseases or the development of autoantibodies is well established in non-transplanted patients, but few data are available about transplanted patients. It is unclear whether inte...
conclusions more than one-quarter of treatment-experienced patients with hcv genotype 3 achieved svr after re-treatment with consensus interferon plus ribavirin. objectives we aimed to assess the efficacy and safety of cifn and ribavirin in non-responders and relapsers to pegylated interferon with ribavirin therapy. patients and methods this open-label investigator-initiated study included 44 p...
hepatitis c virus (hcv) has chronically infected million peoples worldwide. spontaneous viral clearance occurs in 25% of affected patients. the standard regimen to treat hcv infection is the combination of pegylated interferon and ribavirin.
We have previously described the safety and efficacy of pegylated interferon-α2a therapy in a cohort of 62 patients with myeloproliferative neoplasm-associated myelofibrosis followed in centers affiliated to the French Intergroup of Myeloproliferative neoplasms. In this study, we report their long-term outcomes and correlations with mutational patterns of driver and non-driver mutations analyze...
Pegylated interferon remains the first line treatment for patients with hepatitis D virus and more than one year therapy may be necessary. Interferon a has the most extensive clinical application and is used for the treatment of chronic hepatitis B and D virus as well as HCV infections. The attachment of polyethylene glycol to interferon increases its half-life. Treatment with peg interferon is...
a 46-year-old woman presented with progressive dyspnea and cough. she was a known case of chronic hepatitis c (hcv) treated with pegylated (peg)-interferon. complete pulmonary studies and biopsy were compatible with bronchiolitis oblitrans with organizing pneumonia (boop) secondary to peg-interferon. she discontinued peg-interferon and was given a short course of steroids, after which the condi...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید